Company Overview

Company OverviewCHA Biotech History


· Company name changed to CHA Biotech
· Equity Spin-off: CHA Diostech(Optical Business, KOSDAQ: 196450)
· Jong Soo Choi appointed as CEO
· Human embryonic stem cell derived RPE cell therapy for Stargardt Macular
  Degeneration received Orphan Drug Designation(first in Korea)
· Phase I/IIa IND approval for Stroke received from MFDS in Korea(eCASs)
· CHA Biotech’s Cord Blood Bank, i-Cord, received 2014 The Customer
   Trust Brand Award(Hankyung Business)
· Injection to patients in phase I clinical trial for Stargardt Macular Degeneration
  conducted in Korea completed(MA09-hRPE)

· Injection to 1st patient in phase I clinical trial for Stargardt Macular
Degeneration conducted in Korea completed(MA09-hRPE)
· Licensing Agreement between CHA Biotech and Pluristem Therapeutics in
Israel executed
· Physical Division: CHA Healthcare(Hospital Operation Business), CHA Meditech
(Bio Development Business)
· Asset Purchase Agreement with CMG Pharmaceutical executed
(Oral Thin Film Pharmaceutical)



· Phase I/IIa IND approval for Age-related Macular Degeneration(dry type)
  received from MFDS in Korea(MA09-hRPE)
· Injection to 1st patients in phase I/IIa clinical trial for Age-related Macular
  Degeneration(dry type)conducted in Korea completed(MA09-hRPE)
· CMG Pharmaceutical(formerly, Sky New Pharm, KOSDAQ: 058820) acquired
· Won Suk Yang appointed as CEO
· Stem cell banking consignment agreement executed with Stem Union in
  Hong Kong

· SCRMI, a US subsidiary company, succeeded to manufacture and induce differentiation of world’s first platelets generated from human embryonic stem cells
· Phase I IND approval for Stargardt Macular Degeneration received from MFDS
in Korea(MA09-hRPE, World’s first ES cell therapy)
· Approval for establishment of private cord blood bank(i-cord) received from
MHW in Korea
· Recorded over 600 cases of cord blood transplant operation(first time in Korea)
· CHA Vaccine Institute(formerly, Dubeel) acquired



· Future-oriented anti-aging life center CHAUM opened
· Young Key Hwang appointed as Chairman and CEO
· Biotechnology cosmetic products “OHUI the first” and “Tervina” launched in
  collaboration with LG H&H   
· US hospital, LA HPMC, received American Surgical Association Award

CEO Message
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Business
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
IR Presentations